<DOC>
	<DOCNO>NCT02864784</DOCNO>
	<brief_summary>Studies objective : To evaluate safety , tolerability efficacy AMOR-1 give combination ZA Denosumab compare placebo give ZA Denosumab outline : - Safety Tolerability : - Adverse event ( AEs ) serious AEs - Safety laboratory measurement - Hypercalcemic hypercalciuric episodes - Treatment withdrawal due AEs overall Efficacy : - Skeletal Related Events ( SREs ) - Measurable evaluable disease progression - Progression Free Survival ( PFS ) - Pain assessment via VAS scale</brief_summary>
	<brief_title>Investigating Safety , Tolerability Efficacy Amorphous Calcium Carbonate ( ACC ) Treatment Subjects With CRPC</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Bone Neoplasms</mesh_term>
	<mesh_term>Bone Marrow Diseases</mesh_term>
	<mesh_term>Calcium , Dietary</mesh_term>
	<mesh_term>Denosumab</mesh_term>
	<mesh_term>Calcium Carbonate</mesh_term>
	<criteria>1 . Age &gt; 18 year 2 . Histologic proof Castrate Resistant Prostate Cancer Bone Metastasis 3 . Systemic steroid allow need hormonal therapy 4 . Previous radiation therapy must complete four week prior enrollment study , unless subject radiotherapy rescue therapy . Subjects must recover side effect . 5 . The last dose chemotherapy must complete least four week prior enrollment study , subject must recover side effect . 6 . Subjects must performance status 02 ECOG Scale . 7 . Subjects must pretreatment ( obtain &lt; 7 day prior treatment ) granulocyte count &gt; 2,000/μL , platelet count &gt; 100,000/μL , WBC &gt; 3,000/μL , hemoglobin ≥ 10.0 g/dL , serum creatinine &lt; 1.5 mg/dL , bilirubin &lt; 1.5 mg/dL , ALT/AST 3x upper limit normal ( 5x elevation due liver metastasis ) . 8 . Subjects must normocalcemic upon study entry . 9 . Subjects must Vitamin D sufficient upon study entry , define 25 ( OH ) D serum level &gt; 20 ng/mL ( 50 nmol/L ) accord document compose Food Nutrition Board Institute Medicine , USA . If subject Vitamin D insufficient deficient , load dose Vitamin D3 administer follow : If serum 25 ( OH ) D level 1220 ng/mL ( 3050 nmol/L ) load oral dose 50,000 IU Vitamin D3 administer twice 35 day dos . If serum 25 ( OH ) D level ≤ 12 ng/mL ( 30 nmol/L ) , load oral dose 50,000 IU Vitamin D3 administer three time 35 day dos . Serum 25 ( OH ) D level check 12 week follow last loading . 10 . Regardless Vitamin D level , subject receive daily maintenance dose 1000 IU Vitamin D3 , take morning breakfast . 11 . Estimated life expectancy &gt; 3 month . 12 . Subjects must accessible followup . 13 . Written inform consent obtain . 1 . Concurrent treatment acute anticancer therapy 2 . Hormonal corticosteroid therapy Skeletal Related Events allow 3 . Sarcoidosis 4 . Hypercalcemia 5 . Hypophosphatemia 6 . Hypoparathyroidism/Hyperparathyroidism 7 . Major surgery within 4 week anticipate inception AMOR1therapy 8 . Serious intercurrent infection nonmalignant medical illness uncontrolled whose control may jeopardize complication therapy 9 . Psychiatric disorder render subject incapable comply requirement protocol 10 . Any illness condition deem investigator contraindicate treatment AMOR1 ZA Denosumab 11 . Hypersensitivity ZA Denosumab Abiraterone acetate Enzalutamide , bisphosphonates follow excipients : Mannitol Sodium citrate . 12 . Active cancer treatment except hormonal</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>